AU2022266680A1 - 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression - Google Patents

19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression Download PDF

Info

Publication number
AU2022266680A1
AU2022266680A1 AU2022266680A AU2022266680A AU2022266680A1 AU 2022266680 A1 AU2022266680 A1 AU 2022266680A1 AU 2022266680 A AU2022266680 A AU 2022266680A AU 2022266680 A AU2022266680 A AU 2022266680A AU 2022266680 A1 AU2022266680 A1 AU 2022266680A1
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
subject
acceptable salt
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022266680A
Other languages
English (en)
Inventor
Bambang Senoaji Adiwijaya
Ryan ARNOLD
Vijayveer BONTHAPALLY
Helen Anne COLQUHOUN
James Doherty
Joi Lisa DUNBAR
Handan GUNDUZ-BRUCE
Jeffrey Martin JONAS
Stephen Jay KANES
Robert Alfonso LASSER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics LLC
Original Assignee
Sage Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics LLC filed Critical Sage Therapeutics LLC
Publication of AU2022266680A1 publication Critical patent/AU2022266680A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022266680A 2021-04-29 2022-04-29 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression Pending AU2022266680A1 (en)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202163181743P 2021-04-29 2021-04-29
US63/181,743 2021-04-29
US202163197025P 2021-06-04 2021-06-04
US63/197,025 2021-06-04
US202163210810P 2021-06-15 2021-06-15
US63/210,810 2021-06-15
US202163239096P 2021-08-31 2021-08-31
US63/239,096 2021-08-31
US202163285812P 2021-12-03 2021-12-03
US63/285,812 2021-12-03
US202163289506P 2021-12-14 2021-12-14
US202163289520P 2021-12-14 2021-12-14
US63/289,506 2021-12-14
US63/289,520 2021-12-14
US202263298601P 2022-01-11 2022-01-11
US63/298,601 2022-01-11
PCT/US2022/026920 WO2022232504A1 (en) 2021-04-29 2022-04-29 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression

Publications (1)

Publication Number Publication Date
AU2022266680A1 true AU2022266680A1 (en) 2023-11-02

Family

ID=81748925

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022266680A Pending AU2022266680A1 (en) 2021-04-29 2022-04-29 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression

Country Status (11)

Country Link
US (1) US20240216395A1 (cg-RX-API-DMAC7.html)
EP (2) EP4768044A2 (cg-RX-API-DMAC7.html)
JP (2) JP2024515829A (cg-RX-API-DMAC7.html)
KR (1) KR20240006026A (cg-RX-API-DMAC7.html)
AU (1) AU2022266680A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022264A2 (cg-RX-API-DMAC7.html)
CA (1) CA3218072A1 (cg-RX-API-DMAC7.html)
IL (1) IL307991A (cg-RX-API-DMAC7.html)
MX (1) MX2023012727A (cg-RX-API-DMAC7.html)
TW (1) TW202308654A (cg-RX-API-DMAC7.html)
WO (1) WO2022232504A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3678670A1 (en) * 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
JP2022514510A (ja) * 2018-12-14 2022-02-14 プラクシス プレシジョン メディスンズ,インコーポレイテッド うつ病の治療方法
CA3187178A1 (en) 2020-07-20 2022-01-27 Sage Therapeutics, Inc. Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof
JP2025508406A (ja) * 2022-02-16 2025-03-26 セージ セラピューティクス, インコーポレイテッド Cns関連障害を処置するための神経活性ステロイド

Also Published As

Publication number Publication date
EP4329770A1 (en) 2024-03-06
CA3218072A1 (en) 2022-11-03
US20240216395A1 (en) 2024-07-04
WO2022232504A1 (en) 2022-11-03
JP2024515829A (ja) 2024-04-10
JP2025111701A (ja) 2025-07-30
TW202308654A (zh) 2023-03-01
MX2023012727A (es) 2023-11-08
KR20240006026A (ko) 2024-01-12
IL307991A (en) 2023-12-01
EP4768044A2 (en) 2026-07-01
BR112023022264A2 (pt) 2024-01-23

Similar Documents

Publication Publication Date Title
US20240216395A1 (en) 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
US20250339447A1 (en) 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
KR20240148425A (ko) Cns-관련 장애의 치료를 위한 신경활성 스테로이드
US20230018765A1 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
EP4308162A1 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder
US10278977B2 (en) Methods for treating hypersomnolence
WO2025122747A1 (en) Treatment of moderate-to-severe asthma by administering rilzabrutinib
AU2024332373A1 (en) Methods of using factor b inhibitors
CN117580581A (zh) 用于治疗重度抑郁障碍和产后抑郁症的19-去甲c3,3-二取代的c21-n-吡唑基类固醇
WO2023159035A1 (en) Neuroactive steroids for treatment of cns-related disorders

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE APPLICANT NAME TO SAGE THERAPEUTICS, LLC